The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2024 | Impact of severe esophagitis on outcomes in radiotherapy-treated LS SCLC
Bjørn Henning Grønberg, MD, PhD, Norwegian University of Science and Technology, Trondheim, Norway, discusses a Phase II trial (NCT02041845) exploring whether severe esophagitis during twice-daily thoracic radiotherapy (TRT) in limited-stage small-cell lung cancer (LS SCLC) affects long-term outcomes. Results showed no significant differences in progression-free survival (PFS) or overall survival (OS) between patients with or without severe esophagitis, suggesting that concerns over esophagitis should not hinder the implementation of higher-dose radiotherapy. This interview took place at the 2024 World Conference on Lung Cancer (WCLC) in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
